Overview
Centauri Therapeutics, a UK-based immunotherapy company, has raised £6 million in a Series A extension led by the AMR Action Fund, bringing total Series A funding to £30 million. The funds will be used to complete Phase I clinical studies for ctx-187, a broad-spectrum antimicrobial targeting multidrug-resistant gram-negative bacteria, and to prepare for Phase II trials. The AMR Action Fund aims to support the advancement of ctx-187 through key safety data generation.
Products
Loading...
Recent Deals
Investors: AMR Action Fund
Centauri Therapeutics, a UK-based immunotherapy company, has raised £6 million in a Series A extension led by the AMR Action Fund, bringing total Series A funding to £30 million. The funds will be used to complete Phase I clinical studies for ctx-187, a broad-spectrum antimicrobial targeting multidrug-resistant gram-negative bacteria, and to prepare for Phase II trials. The AMR Action Fund aims to support the advancement of ctx-187 through key safety data generation.